Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 1
2007 2
2008 2
2009 2
2010 1
2011 3
2012 4
2013 4
2016 4
2017 3
2018 6
2019 4
2020 5
2021 5
2022 4
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Emerging therapeutic opportunities for integrin inhibitors.
Slack RJ, Macdonald SJF, Roper JA, Jenkins RG, Hatley RJD. Slack RJ, et al. Nat Rev Drug Discov. 2022 Jan;21(1):60-78. doi: 10.1038/s41573-021-00284-4. Epub 2021 Sep 17. Nat Rev Drug Discov. 2022. PMID: 34535788 Free PMC article. Review.
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.
Hirani N, MacKinnon AC, Nicol L, Ford P, Schambye H, Pedersen A, Nilsson UJ, Leffler H, Sethi T, Tantawi S, Gravelle L, Slack RJ, Mills R, Karmakar U, Humphries D, Zetterberg F, Keeling L, Paul L, Molyneaux PL, Li F, Funston W, Forrest IA, Simpson AJ, Gibbons MA, Maher TM. Hirani N, et al. Among authors: slack rj. Eur Respir J. 2021 May 27;57(5):2002559. doi: 10.1183/13993003.02559-2020. Print 2021 May. Eur Respir J. 2021. PMID: 33214209 Free PMC article. Clinical Trial.
Galectin-3: therapeutic targeting in liver disease.
Mackinnon AC, Tonev D, Jacoby B, Pinzani M, Slack RJ. Mackinnon AC, et al. Among authors: slack rj. Expert Opin Ther Targets. 2023 Jul-Dec;27(9):779-791. doi: 10.1080/14728222.2023.2258280. Epub 2023 Sep 15. Expert Opin Ther Targets. 2023. PMID: 37705214 Review.
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease.
Zetterberg FR, MacKinnon A, Brimert T, Gravelle L, Johnsson RE, Kahl-Knutson B, Leffler H, Nilsson UJ, Pedersen A, Peterson K, Roper JA, Schambye H, Slack RJ, Tantawi S. Zetterberg FR, et al. Among authors: slack rj. J Med Chem. 2022 Oct 13;65(19):12626-12638. doi: 10.1021/acs.jmedchem.2c00660. Epub 2022 Sep 26. J Med Chem. 2022. PMID: 36154172 Free PMC article.
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants.
Aslanis V, Slack RJ, MacKinnon AC, McClinton C, Tantawi S, Gravelle L, Nilsson UJ, Leffler H, Brooks A, Khindri SK, Marshall RP, Pedersen A, Schambye H, Zetterberg F. Aslanis V, et al. Among authors: slack rj. Cancer Chemother Pharmacol. 2023 Mar;91(3):267-280. doi: 10.1007/s00280-023-04513-y. Epub 2023 Mar 13. Cancer Chemother Pharmacol. 2023. PMID: 36914828 Free PMC article. Clinical Trial.
Discovery of Selective and Orally Available Galectin-1 Inhibitors.
Zetterberg FR, Diehl C, Håkansson M, Kahl-Knutson B, Leffler H, Nilsson UJ, Peterson K, Roper JA, Slack RJ. Zetterberg FR, et al. Among authors: slack rj. J Med Chem. 2023 Dec 28;66(24):16980-16990. doi: 10.1021/acs.jmedchem.3c01787. Epub 2023 Dec 7. J Med Chem. 2023. PMID: 38059452
52 results